Antibody Shields Immune Cells from Dangerous Hospital-Acquired Bacterium

A newly developed monoclonal antibody is showing promise in protecting immune system cells from the harmful effects of pyocyanin, a toxin produced by the dangerous, antibiotic-resistant bacterium Pseudomonas aeruginosa. Researchers at the Nanobiotechnology for Diagnostics group (Nb4D) at the Institute of Advanced Chemistry of Catalonia (IQAC), part of the Spanish National Research Council (CSIC), have demonstrated the antibody’s effectiveness in laboratory cell cultures.

The Threat of Pseudomonas aeruginosa

Pseudomonas aeruginosa is a globally significant pathogen, recognized by the World Health Organization as a priority pathogen requiring urgent innovative therapeutic strategies.¹ Its ability to develop resistance to most available antibiotics makes it a particularly serious threat, especially in hospital-acquired infections. The bacterium’s virulence is largely attributed to pyocyanin, a toxin that compromises immune cells and disrupts inflammatory responses.¹

An “Anti-Virulence” Approach

The research, published in ACS Pharmacology & Translational Science, takes an innovative “anti-virulence” approach.² Instead of attempting to kill the bacteria directly – a strategy that can accelerate antibiotic resistance – the researchers focused on neutralizing pyocyanin. By disarming the pathogen, the therapeutic strategy aims to reduce selective pressure for resistance development.¹

mAb122: A Targeted Antibody

The IQAC researchers developed a monoclonal antibody, named mAb122, specifically designed to bind to pyocyanin and prevent its damaging effects.¹ In laboratory tests using macrophages (a type of immune cell) exposed to pyocyanin, mAb122 significantly reduced cellular damage and increased immune cell survival. Importantly, the antibody showed no toxic effects on its own.¹

Reducing Selective Pressure for Resistance

“Unlike conventional antibiotics, this strategy does not aim to directly eliminate the microorganism, but rather to neutralize one of its main virulence mechanisms,” explains Pilar Marco, head of the Nanobiotechnology for Diagnostics group at IQAC.¹ “With this type of anti-virulence therapy, selective pressure that favors the emergence of resistance is reduced.” This approach seeks to disarm the bacterium rather than kill it, decreasing the likelihood of antibiotic-resistance mutations.

Impact on Inflammation

The study too investigated the antibody’s effect on the inflammatory response, as pyocyanin alters the production of cytokines involved in immune regulation. While mAb122 did modify some cytokine levels, further research is needed to fully understand its impact on inflammation and determine if it can be appropriately modulated.¹

Future Directions

Neutralizing pyocyanin with antibodies represents a promising strategy for protecting immune cells against Pseudomonas aeruginosa. While the research is still in its early stages, the in vitro results pave the way for future in vivo studies to evaluate safety and efficacy in living organisms.¹ If confirmed, this approach could become a more specific and safer therapeutic tool for combating infections caused by multidrug-resistant bacteria, particularly in hospital settings. The next steps involve evaluating the antibody’s protective effect in animal models and assessing potential inflammatory responses.

Source: Rodríguez-Urretavizcaya, B., et al. (2025). Anti-pyocyanin Antibody Exhibits Cytotoxicity Protective Effects on Macrophages: A Promising Innovative Therapeutic Approach for Pseudomonas aeruginosa Infections. ACS Pharmacology & Translational Science. 2